← Back to news
Y

Yahoo Finance

International Business Machines (IBM): Could It Break Trillion Dollar Barrier?

Y

Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)

Y

Edwards Lifesciences raises FY26 guidance following strong Q1

Y

S&W appoints tax valuer Pavan Singh as partner in London

Y

Apple Stock, Back In Growth Mode, In Earnings Spotlight With Google, Meta, Amazon

Y

Nestlé job cuts begin in Europe under plan to eliminate 16,000 positions

Y

Nowadays launches low-THC drinks line

Y

Better International ETF: iShares' IEMG vs. State Street's SPGM

Y

Companies turn to temporary hires amid reluctance to commit to full-timers

Y

AFRC hits PwC with $38.3m fine and curbs over Evergrande audits

Y

Citi Brings Google-Powered AI Avatar to Wealth Clients

Y

Norfolk Southern (NSC) Q1 2026 Earnings Transcript

Y

Americans are addicted to auto debt. How sacrificing a new car purchase now could mean an extra $600,000 for you later

Y

Will Stride (LRN) be able to Navigate Challenges?

Y

US chipmakers hit record highs as Intel turbocharges AI rally

Y

Applied Materials (AMAT): Analyzing the Next Stock to Breach the Trillion Dollar Barrier

Y

Helix, Hornbeck sign all-stock deal to form integrated offshore group

Y

Battle Of The Weight-Loss Pills Continues With A Shocking Twist

Y

Here’s Why Fiduciary Management Bets on Booking Holdings (BKNG), The Largest Online Travel Agency

Y

Cisco Systems (CSCO): Can It Hit Trillion Dollar Milestone?

Y

Palantir Technologies (PLTR): The Trillion-Dollar Contender Nobody Is Talking About

Y

Intel Corporation (INTC): Trillion Dollar Barrier Not a Distant Dream

Y

Flagstar (FLG) Q1 2026 Earnings Transcript

Y

What Makes Huron Consulting Group (HURN) a Compelling Investment Bet?

Y

Advanced Micro Devices (AMD): Why This Stock Could Break Trillion Dollar Market Cap

Y

The Market Is Unpredictable, and That Makes This the Perfect Time to Buy This Growth Stock

Y

Alpha and Omega Semiconductor's CFO Dumped Over 8,000 Company Shares. Here's What That Means for Investors.

Y

5 Insurance Policies You Are (Probably) Overpaying For

Y

He Never Had To Work And Now His Trust Fund Is Drying Up At 23. Dave Ramsey Says, 'Go Buy A Leaf Blower. Rich People Are Afraid Of Leaves'

Y

Which Is the Better Food and Beverage ETF, Invesco's PBJ or First Trust's FTXG?

Y

Bitcoin Heads For Fourth Weekly Gain

Y

Texas Instruments Soars on Strong Q1 Results. Should You Buy TXN Stock Here?

Y

Salesforce's Q1 2027 Earnings: What to Expect

Y

Stock Market Today: Nasdaq, S&P 500 Score Record Closes; Rally Faces Mag 7 Earnings Test (Live Coverage)

Y

Jefferies Updates Elevance Health, Inc. (ELV) Forecasts After Deeper Analysis of Exchange Segment Dynamics

Y

Jefferies Adjusts The Cigna Group (CI) Target Lower After Health Insurance Exchange Review

Y

Evercore ISI Says Sun Pharma Deal Talk for Organon & Co. (OGN) Lacks Confirmation, Remains Speculative

Y

Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns

Y

IBM, Honeywell, and Cisco Stocks Remind Us That If You’re Not Invested in AI, You’re Losing in Today’s Market

Y

Inspire Medical Systems, Inc. (INSP) PT Reduced to $64 as Truist Updates MedTech Outlook Ahead of Q1

Y

Citizens Lowers MiMedx Group, Inc. (MDXG) Valuation to $7 Amid Sluggish Recovery Trends

Y

ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds

Y

RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1

Y

Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead

Y

ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia

Y

Insider Trading Scandals Compound Prediction Market Pressures; Two Stocks Downgraded

Y

BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models

Y

Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib

Y

ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends

Y

Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook

Y